scholarly journals QoL of ex-leprosy patients’ children in Vietnam

2020 ◽  
Vol 89 (1) ◽  
pp. 1-11
Author(s):  
Hiroyuki WATANABE ◽  
Vu Tuan Anh ◽  
Huynh Cong Ai ◽  
Tran Xuan Vy ◽  
Tran Sy Duy ◽  
...  
Keyword(s):  
Leprosy Patients

Recent Advancement in the Diagnosis and Treatment of Leprosy

2018 ◽  
Vol 18 (18) ◽  
pp. 1550-1558
Author(s):  
Muhammad Aamir ◽  
Asma Sadaf ◽  
Sehroon Khan ◽  
Shagufta Perveen ◽  
Afsar Khan
Keyword(s):  
Vitamin D ◽  
Drug Treatment ◽  
Mycobacterium Leprae ◽  
Neglected Diseases ◽  
Specific Drug ◽  
Genetic Studies ◽  
Vitamin D Receptors ◽  
Micro Rnas ◽  
Leprosy Patients ◽  
Skin Biopsies

Background: Many of the tropical diseases are neglected by the researchers and medicinal companies due to lack of profit and other interests. The Drugs for Neglected Diseases initiative (DNDi) is established to overcome the problems associated with these neglected diseases. According to a report published by the WHO, leprosy (Hansen's disease) is also a neglected infectious disease. Methods: A negligible amount of advancements has been made in last few decades which includes the tools of diagnosis, causes, treatment, and genetic studies of the bacterium (Mycobacterium leprae) that causes leprosy. The diagnosis of leprosy at earlier stages is important for its effective treatment. Recent studies on vitamin D and its receptors make leprosy diagnosis easier at earlier stages. Skin biopsies and qPCR are the other tools to identify the disease at its initial stages. Results: Until now a specific drug for the treatment of leprosy is not available, therefore, Multi-Drug Therapy (MDT) is used, which is hazardous to health. Besides Mycobacterium leprae, recently a new bacterium Mycobacterium lepromatosis was also identified as a cause of leprosy. During the last few years the genetic studies of Mycobacterium leprae, the role of vitamin D and vitamin D receptors (VDR), and the skin biopsies made the treatment and diagnosis of leprosy easier at early stages. The studies of micro RNAs (miRNAs) made it easy to differentiate leprosy from other diseases especially from tuberculosis. Conclusion: Leprosy can be distinguished from sarcoidosis by quantitative study of reticulin fibers present in skin. The treatment used until now for leprosy is multi-drug treatment. The complete genome identification of Mycobacterium leprae makes the research easy to develop target specified drugs for leprosy. Rifampicin, identified as a potent drug, along with other drugs in uniform multi-drug treatment, has a significant effect when given to leprosy patients at initial stages. These are effective treatments but a specific drug for leprosy is still needed to be identified. The current review highlights the use of modern methods for the identification of leprosy at its earlier stages and the effective use of drugs alone as well as in combination.

Unusual non-trophic ulcerations in leprosy: A case series of 17 patients

2021 ◽  
pp. 004947552199849
Author(s):  
Prakriti Shukla ◽  
Kiran Preet Malhotra ◽  
Parul Verma ◽  
Swastika Suvirya ◽  
Abir Saraswat ◽  
...  
Keyword(s):  
Erythema Nodosum ◽  
Case Series ◽  
Lepromatous Leprosy ◽  
Sweet Syndrome ◽  
Erythema Nodosum Leprosum ◽  
Leprosy Patients ◽  
Atypical Presentations ◽  
Neuropathic Ulcers

Non-neuropathic ulcers in leprosy patients are infrequently seen, and atypical presentations are prone to misdiagnosis. We evaluated diagnosed cases of leprosy between January 2017 and January 2020 for the presence of cutaneous ulceration, Ridley–Jopling subtype of leprosy, reactions and histologic features of these ulcerations. Treatment was given as WHO recommended multi-bacillary multi-drug therapy. We found 17/386 leprosy patients with non-neuropathic ulcers. We describe three causes – spontaneous cutaneous ulceration in lepromatous leprosy (one nodular and one diffuse), lepra reactions (five patients with type 1; nine with type 2, further categorised into ulcerated Sweet syndrome-like who also had pseudoepitheliomatous hyperplasia, pustulo-necrotic and necrotic erythema nodosum leprosum) and Lucio phenomenon (one patient). Our series draws attention towards the different faces of non-neuropathic ulcers in leprosy, including some atypical and novel presentations.

scholarly journals Recombinant polypeptide of Mycobacterium leprae as a potential tool for serological detection of leprosy

AMB Express ◽  
2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Marcelo dos Santos Barbosa ◽  
Iara Beatriz Andrade de Sousa ◽  
Simone Simionatto ◽  
Sibele Borsuk ◽  
Silvana Beutinger Marchioro
Keyword(s):  
Large Scale ◽  
Mycobacterium Leprae ◽  
Detection Methods ◽  
Recombinant Polypeptide ◽  
Cell Reactivity ◽  
Tertiary Structures ◽  
Leprosy Patients ◽  
T Cell Reactivity ◽  
Prevention Methods ◽  
Scale Detection

AbstractCurrent prevention methods for the transmission of Mycobacterium leprae, the causative agent of leprosy, are inadequate as suggested by the rate of new leprosy cases reported. Simple large-scale detection methods for M. leprae infection are crucial for early detection of leprosy and disease control. The present study investigates the production and seroreactivity of a recombinant polypeptide composed of various M. leprae protein epitopes. The structural and physicochemical parameters of this construction were assessed using in silico tools. Parameters like subcellular localization, presence of signal peptide, primary, secondary, and tertiary structures, and 3D model were ascertained using several bioinformatics tools. The resultant purified recombinant polypeptide, designated rMLP15, is composed of 15 peptides from six selected M. leprae proteins (ML1358, ML2055, ML0885, ML1811, ML1812, and ML1214) that induce T cell reactivity in leprosy patients from different hyperendemic regions. Using rMLP15 as the antigen, sera from 24 positive patients and 14 healthy controls were evaluated for reactivity via ELISA. ELISA-rMLP15 was able to diagnose 79.17% of leprosy patients with a specificity of 92.86%. rMLP15 was also able to detect the multibacillary and paucibacillary patients in the same proportions, a desirable addition in the leprosy diagnosis. These results summarily indicate the utility of the recombinant protein rMLP15 in the diagnosis of leprosy and the future development of a viable screening test.

Risk factors for type-1 reactions in borderline leprosy patients

The Lancet ◽  
1991 ◽  
Vol 338 (8768) ◽  
pp. 654-657 ◽  
Author(s):  
P.W. Roche ◽  
W.J. Theuvenet ◽  
W.J. Britton
Keyword(s):  
Risk Factors ◽  
Leprosy Patients

Alteration of the cortisol–cortisone shuttle in leprosy type 1 reactions in leprosy patients in Hyderabad, India

2007 ◽  
Vol 109 (1) ◽  
pp. 72-75 ◽  
Author(s):  
Anna K. Andersson ◽  
Sara E. Atkinson ◽  
Saroj Khanolkar-Young ◽  
MeherVani Chaduvula ◽  
Suman Jain ◽  
...  
Keyword(s):  
Leprosy Patients

HLA-DQ molecules and the control ofMycobacterium leprae-specific T cell nonresponsiveness in lepromatous leprosy patients

1990 ◽  
Vol 20 (10) ◽  
pp. 2347-2350 ◽  
Author(s):  
Tom H. M. Ottenhoff ◽  
Charlotte Walford ◽  
Yasuharu Nishimura ◽  
N. B. B. Reddy ◽  
Takehiko Sasazuki
Keyword(s):  
T Cell ◽  
Lepromatous Leprosy ◽  
Hla Dq ◽  
Leprosy Patients

S275 – Nasal Morphology and Nasal Patency in Leprosy Patients

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P167-P167
Author(s):  
Maria Teresa Torres Larrosa ◽  
Luis Jorge Peréz Peréz ◽  
Juan-Jose Artazkoz-del Toro
Keyword(s):  
Drug Therapy ◽  
Therapy Group ◽  
Control Group ◽  
Nasal Patency ◽  
Multidrug Therapy ◽  
Airway Patency ◽  
Expiratory Resistance ◽  
Leprosy Patients ◽  
The Right ◽  
The Impact

Objectives 1) To assess the impact of multi-drug leprosy therapy on the development of nasal deformities and nasal airway patency. 2) Evaluate the nasal morphology and nasal patency in leprosy patients treated with the multidrug therapy in comparison with patients treated with 1 drug therapy and a group of healthy volunteers. Methods In an overall group of 84 patients studied, 38 were treated with a therapy based on a single drug, and 22 were treated with multi-drug therapy, while 24 subjects formed a control group. We used anterior rhinoscopy to analised the morphology of the nose. We meassured the nasal inspiratory and expiratory resistance of the right and left nostrils and total nasal inspiratory and expiratory resistance at a transnasal pressure of 150 Pa. by using active anterior rhinomanometry. The statistical analysis was carried out using the Varianza analisys. Results The nasal structures in the 1-drug therapy group underwent bone and cartilaginous resorption with an increase in nasal resistances. We found significant statistical differences between the resistance values obtained in this group and the control group (p<0,05). In the multidrug therapy group, the morphology of the nose remains as in healthy patients. No significant statistical differences were found between the resistance values obtained in the multidrug therapy patients and the control group (P>0,05). Conclusions The multidrug therapy prevents developing nasal deformities and maintains a normal nasal airflow.

Sign in / Sign up

Export Citation Format

Share Document